It is more important than ever to detect and characterize NTRK fusion events. However, not all detection methods are equal. In fact, 60% of NTRK fusion partners can be missed by commercially available amplicon-based NTRK detection assays. RNA-based Hybrid-Capture NGS is the only method that enables capturing all fusions, agnostic of the fusion partner. Learn how Illumina NGS technology detects more fusions, including NTRK fusions. With genomic advancements in comprehensive fusion detection, the possibilities are limitless.)
Dr. Phil Febbo
Chief Medical Officer, Illumina, Inc.
Sue Beruti
Clinical Laboratory, Senior Director
Details
Fill Out Form to Access Webinar
Your email address is never shared with third parties.
- Date & Time
- Jun 1, 2019
- 9:30 AM
- Location
- North America
- Topic
- Oncology